Table 3 Study periods at which measures and data are collected

Demographic information (gender, age, etc.)

X

History of FMS (years of illness)

X

Contact details

X

SCID-I (depression module)

X

Screening measures

 MMSE (cognitive impairment)

X

Primary outcome measure

 FIQR (functional impairment)

X

X

X

Secondary outcome measures

 FSDC (fibromyalginess)

X

X

X

 HADS (anxiety and depression)

X

X

X

 PSS-10 (perceived stress)

X

X

X

 MISCI (subjective cognitive impairment)

X

X

X

 EQ-5D-5L (quality of life)

X

X

 CSRI (health economic evaluation)

X

X

 FFMQ^a (mindfulness facets)

X

X

X

 PCS^a (pain catastrophizing)

X

X

X

 PIPS^a (psychological inflexibility)

X

X

X

 SCS-12^a (self-compassion)

X

X

X

Other measures

 Structural + Functional Neuroimaging data

X

X

 Inflammatory data

X

X

 CEQ (Expectation/Satisfaction with treatment)

X (EXP)

X (SAT)

 PGIC & PSIC (Impression of change)

X

X

 Treatment attendance form: Attendance at each scheduled MBSR/FibroQoL session

X

 Log of MBSR and FibroQoL practices

X

 Treatment fidelity (review of video-taped MBSR sessions) & monitoring of adverse events

X

X

X